-+ 0.00%
-+ 0.00%
-+ 0.00%
IDEAYA Plans Phase 3 Trial of IDE849 in Refractory Neuroendocrine Carcinomas by End-2026
Share
Listen to the news
IDEAYA Plans Phase 3 Trial of IDE849 in Refractory Neuroendocrine Carcinomas by End-2026
  • IDEAYA Biosciences plans to launch IDE849 registration trials by year-end 2026 following FDA discussions on neuroendocrine carcinoma study designs.
  • A single-arm cohort of approximately 90 previously treated gastroenteropancreatic neuroendocrine carcinoma patients could support accelerated approval.
  • A randomized Phase 3 trial across multiple neuroendocrine carcinoma subtypes aims to confirm clinical benefit for full approval.
  • A separate randomized Phase 3 trial will evaluate IDE849 in extensive-stage small cell lung cancer following Imdelltra treatment.
  • Results presented at ESMO in October showed tumor responses in previously treated neuroendocrine carcinoma, with a favorable safety profile.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611161605PR_NEWS_USPR_____SF97990) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending